Pirtobrutinib can extend the benefits of Bruton tyrosine kinase (BTKi) in patients with CLL / SLL who are resistant to covalent BTKi
CLL patients infected with SARS-CoV-2 last year had non-lethal outcomes if they were treated with the new medications and treatment protocols
We discuss enitociclib, an experimental CDK9 inhibitor in development for treating NHL and CLL.
Starting treatment for CLL / SLL requires a complex decision-making process. There are several well-established choices
The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)
We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.
New survey data shows that the most important treatment attribute for patients with CLLis that the treatment increases their chances.
Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL
Study shows that patients with relapsed/refractory CLL recovered immune function after fixed-duration treatment with venetoclax + rituximab.
